MX2023004598A - Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias. - Google Patents

Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.

Info

Publication number
MX2023004598A
MX2023004598A MX2023004598A MX2023004598A MX2023004598A MX 2023004598 A MX2023004598 A MX 2023004598A MX 2023004598 A MX2023004598 A MX 2023004598A MX 2023004598 A MX2023004598 A MX 2023004598A MX 2023004598 A MX2023004598 A MX 2023004598A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding molecules
fusions
immune cell
cell function
Prior art date
Application number
MX2023004598A
Other languages
English (en)
Inventor
Wei Chen
Ivana Djuretic
Yik Andy Yeung
Paul Bessette
Sherman Michael Chin
Kelly Dare Moynihan
Henry C Nguyen
Irene Ni
Danielle C Pappas
Terrence Park
Original Assignee
Asher Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asher Biotherapeutics Inc filed Critical Asher Biotherapeutics Inc
Publication of MX2023004598A publication Critical patent/MX2023004598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente moléculas de unión al antígeno anti-CD8 y polipéptidos de fusión que comprenden las moléculas de unión al antígeno CD8 para modular selectivamente la función de los linfocitos T CD8+ sobre otras células inmunitarias. Además, la presente descripción también proporciona polinucleótidos que codifican las moléculas de unión al antígeno y los polipéptidos de fusión descritos, y vectores y células hospedadoras que comprenden tales polinucleótidos. La presente descripción proporciona además métodos para producir moléculas de unión al antígeno y polipéptidos de fusión, composiciones farmacéuticas que los comprenden y usos de estos.
MX2023004598A 2020-10-23 2021-10-22 Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias. MX2023004598A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063105162P 2020-10-23 2020-10-23
US202063121663P 2020-12-04 2020-12-04
US202163190669P 2021-05-19 2021-05-19
PCT/US2021/056312 WO2022087458A1 (en) 2020-10-23 2021-10-22 Fusions with cd8 antigen binding molecules for modulating immune cell function

Publications (1)

Publication Number Publication Date
MX2023004598A true MX2023004598A (es) 2023-06-29

Family

ID=81289477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004598A MX2023004598A (es) 2020-10-23 2021-10-22 Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.

Country Status (10)

Country Link
US (1) US20220162314A1 (es)
EP (1) EP4232071A1 (es)
JP (1) JP2023548045A (es)
KR (1) KR20230112632A (es)
AU (1) AU2021364387A1 (es)
CA (1) CA3199447A1 (es)
IL (1) IL302276A (es)
MX (1) MX2023004598A (es)
TW (1) TW202233673A (es)
WO (1) WO2022087458A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190352363A1 (en) 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018234628B2 (en) 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
WO2024073572A2 (en) * 2022-09-29 2024-04-04 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for treating chronic viral infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6940003B1 (en) * 1998-12-03 2005-09-06 E. I. Du Pont De Nemours And Company Plan lecithin: cholesterol acyltransferases
LT2521568T (lt) * 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX364738B (es) * 2012-06-15 2019-05-03 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos.
CA2878626A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
US10544187B2 (en) * 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
ME03724B (me) * 2014-09-05 2021-01-20 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
BR112018015485A2 (pt) * 2016-02-06 2018-12-18 Epimab Biotherapeutics Inc imunoglobulina fabs-in-tandem e usos da mesma
MY197688A (en) * 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
AU2018312251A1 (en) * 2017-07-31 2020-02-20 Trishula Therapeutics, Inc. Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies
SG11202000387YA (en) * 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
EP3759129A1 (en) * 2018-02-28 2021-01-06 Pfizer Inc Il-15 variants and uses thereof
EP3778635A4 (en) * 2018-04-09 2022-01-26 Origincell Therapeutics Co., Ltd. ANTI-PD-L1 ANTIBODIES AND ITS USE
AU2019288484A1 (en) * 2018-06-22 2021-01-21 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
GB201900732D0 (en) * 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
AU2021364387A1 (en) 2023-06-15
WO2022087458A1 (en) 2022-04-28
TW202233673A (zh) 2022-09-01
IL302276A (en) 2023-06-01
KR20230112632A (ko) 2023-07-27
CA3199447A1 (en) 2022-04-28
US20220162314A1 (en) 2022-05-26
EP4232071A1 (en) 2023-08-30
JP2023548045A (ja) 2023-11-15

Similar Documents

Publication Publication Date Title
MX2023004598A (es) Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
WO2020247843A3 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
IL308851A (en) Multimeric polypeptides modulate T cells and methods for their use
MX2022012409A (es) Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores.
MX2021009087A (es) Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
MX2020012927A (es) Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
MX2022008602A (es) Polinucleotidos que codifican interleucina-12 (il 12) y usos de los mismos.
MX2015008329A (es) Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
WO2020052692A3 (en) Binding molecules against cd3 and uses thereof
WO2016134371A3 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
AU2019343184A8 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
BRPI0508551A (pt) seqüências de ácidos nucléicos de lactobacillus acidophilus que codificam proteìnas relacionadas à utilização de carboidrato e usos dessas
MX2020010461A (es) Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
WO2009051555A3 (en) Modified mhc class i binding peptides
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
MX2021001771A (es) Polipéptidos del receptor de antígeno quimérico en combinación con moléculas del metabolismo trans que modulan el ciclo de krebs y usos terapéuticos de los mismos.
CR20210370A (es) Neoantígenos prostáticos y sus usos
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
MX2023007282A (es) Moleculas de union al antigeno especificas para la variante ror1.
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
CL2020002950A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878)
WO2019006401A3 (en) LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
EP3988563A3 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
WO2020188348A3 (en) A2/ny-eso-1 specific t cell receptors and uses thereof
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma